[go: up one dir, main page]

EA201000803A1 - Производные хинолина и их применение - Google Patents

Производные хинолина и их применение

Info

Publication number
EA201000803A1
EA201000803A1 EA201000803A EA201000803A EA201000803A1 EA 201000803 A1 EA201000803 A1 EA 201000803A1 EA 201000803 A EA201000803 A EA 201000803A EA 201000803 A EA201000803 A EA 201000803A EA 201000803 A1 EA201000803 A1 EA 201000803A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
application
quinoline derivatives
psoriasis
atherosclerosis
Prior art date
Application number
EA201000803A
Other languages
English (en)
Other versions
EA018798B1 (ru
Inventor
Якоб Вестман
Наталья Нехотяева
Йохан Ванберг
Ульрика Бекман
Йохан Мальм
Original Assignee
Кланотек Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кланотек Аб filed Critical Кланотек Аб
Publication of EA201000803A1 publication Critical patent/EA201000803A1/ru
Publication of EA018798B1 publication Critical patent/EA018798B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Соединение формулы (I)а также его фармацевтически приемлемые соли. Фармацевтическая композиция, содержащая терапевтически эффективное количество соединения. Соединение является применимым для лечения рака, диабетической ретинопатии, связанной с возрастом дегенерации желтого пятна, воспаления, "удара" (мозгового кровоизлияния), ишемии миокарда, атеросклероза, макулярного отека или псориаза.
EA201000803A 2007-11-15 2008-11-14 Производные хинолина и их применение EA018798B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98814707P 2007-11-15 2007-11-15
EP07120799 2007-11-15
PCT/EP2008/065596 WO2009063070A2 (en) 2007-11-15 2008-11-14 Quinoline derivatives and their use as tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201000803A1 true EA201000803A1 (ru) 2011-02-28
EA018798B1 EA018798B1 (ru) 2013-10-30

Family

ID=39295948

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000803A EA018798B1 (ru) 2007-11-15 2008-11-14 Производные хинолина и их применение

Country Status (21)

Country Link
US (2) US8557843B2 (ru)
EP (1) EP2220047B1 (ru)
JP (1) JP5565841B2 (ru)
KR (1) KR101572929B1 (ru)
CN (1) CN103476755B (ru)
AU (1) AU2008322858B2 (ru)
BR (1) BRPI0820210A2 (ru)
CA (1) CA2705820C (ru)
DK (1) DK2220047T3 (ru)
EA (1) EA018798B1 (ru)
ES (1) ES2540219T3 (ru)
HR (1) HRP20150583T1 (ru)
HU (1) HUE025421T2 (ru)
IL (1) IL205308A (ru)
MX (1) MX2010005039A (ru)
NZ (1) NZ585090A (ru)
PL (1) PL2220047T3 (ru)
PT (1) PT2220047E (ru)
RS (1) RS54061B1 (ru)
SI (1) SI2220047T1 (ru)
WO (1) WO2009063070A2 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8592592B2 (en) 2010-04-02 2013-11-26 Senomyx, Inc. Sweet flavor modifier
AU2012295255B2 (en) 2011-08-12 2016-04-21 Senomyx, Inc. Sweet flavor modifier
US9376393B2 (en) 2012-01-05 2016-06-28 Clanotech Ab Quinoline compounds which are anti-angiogenic integrin alpha5 beta1 inhibitors for use in the treatment of fibrosis or fibrosis-related diseases
CA2963901A1 (en) 2014-11-07 2016-05-12 Senomyx, Inc. Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB0324270D0 (en) * 2003-10-16 2003-11-19 Univ Edinburgh Improved control of ES cell self-renewal and lineage specification, and medium therefor
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
WO2007139496A1 (en) * 2006-05-30 2007-12-06 Clanotech Ab Quinoline derivatives acting as tyrosine kinase inhibitors
WO2008119771A2 (en) * 2007-03-30 2008-10-09 Clanotech Ab Quinoline-s-carboxylic acid derivatives as tyrosine kinase inhibitors

Also Published As

Publication number Publication date
CA2705820C (en) 2016-06-07
EP2220047A2 (en) 2010-08-25
SI2220047T1 (sl) 2015-07-31
KR101572929B1 (ko) 2015-11-30
JP5565841B2 (ja) 2014-08-06
AU2008322858B2 (en) 2013-05-02
ES2540219T3 (es) 2015-07-09
CA2705820A1 (en) 2009-05-22
JP2011503151A (ja) 2011-01-27
IL205308A0 (en) 2010-12-30
WO2009063070A2 (en) 2009-05-22
CN103476755A (zh) 2013-12-25
WO2009063070A3 (en) 2009-07-23
HRP20150583T1 (hr) 2015-07-31
NZ585090A (en) 2011-09-30
RS54061B1 (sr) 2015-10-30
EA018798B1 (ru) 2013-10-30
PT2220047E (pt) 2015-07-30
AU2008322858A1 (en) 2009-05-22
HUE025421T2 (en) 2016-02-29
DK2220047T3 (en) 2015-06-29
US8557843B2 (en) 2013-10-15
US8957092B2 (en) 2015-02-17
KR20100097158A (ko) 2010-09-02
US20140018388A1 (en) 2014-01-16
BRPI0820210A2 (pt) 2017-05-09
MX2010005039A (es) 2010-07-30
PL2220047T3 (pl) 2015-08-31
EP2220047B1 (en) 2015-05-06
US20110053976A1 (en) 2011-03-03
IL205308A (en) 2015-03-31
CN103476755B (zh) 2015-08-26

Similar Documents

Publication Publication Date Title
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
EA201170607A1 (ru) Акриламидопроизводные, применимые как ингибиторы перехода митохондриальной проницаемости
EA200701808A1 (ru) Производные тетрагидроиндолона и тетрагидроиндазолона
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201200763A1 (ru) Замещенные производные карбамоилметиламиноуксусной кислоты в качестве новых ингибиторов nep
CY1119170T1 (el) Ενωση γουανιδινης
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EA201100503A1 (ru) Глюкозидные производные и их применения
EA201001733A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
PE20141124A1 (es) Derivados de imidazol fusionados, utiles como inhibidores de ido
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
PT2323972E (pt) Compostos de tetraciclina substituídos com c7-flúor
UA107652C2 (en) Carbazole compounds and therapeutic uses of the compounds
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
EA201071040A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40
EA201001772A1 (ru) Производные 3,5-диамино-6-хлорпиразин-2-карбоновой кислоты и их применение в качестве блокаторов эпителиальных натриевых каналов для лечения заболеваний дыхательных путей
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
EA201070442A1 (ru) НОВЫЕ ИНГИБИТОРЫ sEH И ИХ ПРИМЕНЕНИЕ
ECSP045469A (es) El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas
BRPI0719920B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário
WO2011025982A3 (en) Tetracycline compounds
BR112015004523A2 (pt) compostos de tetraciclina

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM